MARKET

ONTX

ONTX

Onconova Therapeutics Inc
NASDAQ
1.140
-0.080
-6.56%
After Hours: 1.200 +0.06 +5.26% 19:30 02/03 EST
OPEN
1.290
PREV CLOSE
1.220
HIGH
1.290
LOW
1.110
VOLUME
194.50K
TURNOVER
0
52 WEEK HIGH
2.040
52 WEEK LOW
0.6200
MARKET CAP
23.86M
P/E (TTM)
-1.3775
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 6d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 01/20 21:31
Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference
NEWTOWN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate i...
GlobeNewswire · 12/07/2022 13:00
Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference
NEWTOWN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate i...
GlobeNewswire · 11/28/2022 13:00
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
Benzinga · 11/16/2022 10:01
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/15/2022 13:31
Why PlayAGS Shares Are Trading Lower By Over 15%; Here Are 33 Stocks Moving Premarket
Benzinga · 11/15/2022 12:49
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/15/2022 10:19
More
About ONTX
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing products for patients with cancer. It has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. It has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib is a multi-targeted kinase inhibitor targeting cyclin-dependent kinases (CDK) 2, 4, 6, and 9, AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R). It is supporting investigator-initiated studies (ISS) that are exploring the use of rigosertib for cancers driven by mutated Ras genes, including a Phase 1/2a study of rigosertib in combination with a PD-1 inhibitor.

Webull offers kinds of Onconova Therapeutics Inc stock information, including NASDAQ:ONTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONTX stock methods without spending real money on the virtual paper trading platform.